Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bacterial Toxin Shows Promise as Potential Anticancer Drug

By LabMedica International staff writers
Posted on 21 Jun 2015
A toxin that increases the virulence of the bacteria that produce it shows promise as a potential anticancer agent.

The bacterium Vibrio vulnificus produces and secretes a toxin of the MARTX (multifunctional-autoprocessing repeats-in-toxin) family. More...
MARTX toxins serve as delivery platforms for cytotoxic effector domains. One of these effector domains, called the domain of unknown function in position 5 (DUF5), has been shown to increase the potency of the V. vulnificus MARTX toxin in mouse virulence studies, indicating DUF5 directly contributes to pathogenesis. DUF5 is localized in the plasma membrane dependent upon its C1 domain, and the cells become rounded dependent upon its C2 domain.

In the current study, investigators at Northwestern University (Chicago, IL, USA) used a combination of genetic, cell biological, and biochemical strategies to probe the mechanism of action of the MARTX C2 domain, to understand the connection of DUF5 to both cytotoxicity and increased virulence of the pathogen.

They reported in the June 8, 2015, online edition of the journal Nature Communications that DUF5 was a site-specific endopeptidase that cleaved both Ras and the closely related small GTPase Rap1. Both proteins are critical for activation of the innate immune response during infection, which explains the crucial role of this effector domain in the increased virulence of V. vulnificus strains that have DUF5.

In addition, the investigators showed that the V. vulnificus MARTX protein could inhibit cancer cell growth by deactivating Ras. This linkage seems justified, as Ras signaling stimulates cell growth and division, and overactive Ras signaling can ultimately lead to cancer. Ras is the most common oncogene in human cancer—mutations that permanently activate Ras are found in 20%–25% of all human tumors and up to 90% in certain types of cancer such as pancreatic cancer.

"What is unique about this study is the ability of the toxin to cleave Ras, rather than modify it, which is a novel mechanism for inactivating Ras," said senior author Dr. Karla Satchell, professor of microbiology and immunology at Northwestern University. "Ras is important for cell proliferation in cancer, so the toxin could potentially be developed as a treatment for different types of tumors. It has been known that Ras has a role in cancer development, and targeting Ras has been one of the hardest challenges of cancer research and drug discovery."

Related Links:

Northwestern University



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.